The estimated Net Worth of James F Young is at least $2.91 Million dollars as of 21 June 2024. James Young owns over 7,500 units of Novavax stock worth over $759,030 and over the last 15 years he sold NVAX stock worth over $1,926,325. In addition, he makes $223,741 as Independent Chairman of the Board at Novavax.
James has made over 19 trades of the Novavax stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 7,500 units of NVAX stock worth $105,675 on 21 June 2024.
The largest trade he's ever made was buying 200,000 units of Novavax stock on 2 December 2011 worth over $292,000. On average, James trades about 24,764 units every 127 days since 2010. As of 21 June 2024 he still owns at least 61,760 units of Novavax stock.
You can see the complete history of James Young stock trades at the bottom of the page.
Dr. James Francis Young Ph.D. serves as Independent Chairman of the Board of the Company. He is Former Chairman of the Board and Chief Executive Officer of Targeted Microwave Solutions, Inc. from 2016 to 2018. Former President, Research and Development, at MedImmune, Inc. Dr. Young has been Chairman of the Board of Novavax, Inc. since April 2011 and a Director since April 2010. Dr. Young held the position of President, Research and Development, at MedImmune, Inc. from 2000 until 2008 and previously served as Executive Vice President, Research and Development from 1999 to 2000, Senior Vice President from 1995 to 1999, and as Senior Vice President, Research and Development from 1989 to 1995. Dr. Young received B.S. degrees in general science and biology from Villanova University, as well as a Ph.D. in microbiology and immunology from Baylor College of Medicine.
As the Independent Chairman of the Board of Novavax, the total compensation of James Young at Novavax is $223,741. There are 8 executives at Novavax getting paid more, with Stanley Erck having the highest compensation of $2,438,560.
James Young is 67, he's been the Independent Chairman of the Board of Novavax since 2011. There are 4 older and 16 younger executives at Novavax. The oldest executive at Novavax, Inc. is Michael McManus, 77, who is the Independent Director.
James's mailing address filed with the SEC is 700 QUINCE ORCHARD ROAD, , GAITHERSBURG, MD, 20878.
Over the last 23 years, insiders at Novavax have traded over $136,088,511 worth of Novavax stock and bought 2,908,869 units worth $5,634,467 . The most active insiders traders include David M Mott, Rajiv I. Modi, and Gary C Evans. On average, Novavax executives and independent directors trade stock every 25 days with the average trade being worth of $907,678. The most recent stock trade was executed by John Trizzino on 19 August 2024, trading 655 units of NVAX stock currently worth $8,050.
novavax, inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. our recombinant nanoparticles and matrix-m™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines. product pipeline our product pipeline targets a variety of infectious diseases with vaccine candidates currently in clinical development for respiratory syncytial virus ("rsv"), seasonal influenza, pandemic influenza, and ebola virus ("ebov"). we have additional preclinical-stage programs for a variety of infectious diseases. corporate overview novavax is headquartered in gaithersburg, maryland with additional facilities in rockville, maryland and uppsala, sweden. novavax is traded on the nasdaq stock market under the symbol nvax and employs over 300 individuals dedicated to developing novel vaccines to address infectious disease.
Novavax executives and other stock owners filed with the SEC include: